JP2025508050A5 - - Google Patents

Info

Publication number
JP2025508050A5
JP2025508050A5 JP2024553353A JP2024553353A JP2025508050A5 JP 2025508050 A5 JP2025508050 A5 JP 2025508050A5 JP 2024553353 A JP2024553353 A JP 2024553353A JP 2024553353 A JP2024553353 A JP 2024553353A JP 2025508050 A5 JP2025508050 A5 JP 2025508050A5
Authority
JP
Japan
Prior art keywords
seq
sequence
amino acid
acid sequence
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508050A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/063795 external-priority patent/WO2023172879A2/en
Publication of JP2025508050A publication Critical patent/JP2025508050A/ja
Publication of JP2025508050A5 publication Critical patent/JP2025508050A5/ja
Pending legal-status Critical Current

Links

JP2024553353A 2022-03-07 2023-03-06 Cd70指向性がん免疫療法のための多重遺伝子編集細胞 Pending JP2025508050A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263268967P 2022-03-07 2022-03-07
US63/268,967 2022-03-07
PCT/US2023/063795 WO2023172879A2 (en) 2022-03-07 2023-03-06 Multiplex gene edited cells for cd70-directed cancer immunotherapy

Publications (2)

Publication Number Publication Date
JP2025508050A JP2025508050A (ja) 2025-03-21
JP2025508050A5 true JP2025508050A5 (cg-RX-API-DMAC7.html) 2026-03-12

Family

ID=87935884

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553353A Pending JP2025508050A (ja) 2022-03-07 2023-03-06 Cd70指向性がん免疫療法のための多重遺伝子編集細胞

Country Status (6)

Country Link
US (1) US20230390392A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482872A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508050A (cg-RX-API-DMAC7.html)
AU (1) AU2023232083A1 (cg-RX-API-DMAC7.html)
CA (1) CA3254363A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023172879A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
MX2022015586A (es) 2020-06-12 2023-03-15 Nkarta Inc Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.
CN117844811A (zh) * 2024-03-08 2024-04-09 上海恒润达生生物科技股份有限公司 靶向敲除CD70基因的sgRNA组合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022311A1 (en) * 1996-05-21 2003-01-30 Dunnington Damien D. Human CIS protein
US20050271660A1 (en) * 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US8067546B2 (en) * 2005-04-19 2011-11-29 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
DK3105317T3 (en) * 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
US11166985B2 (en) * 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
JP2021502077A (ja) * 2017-11-06 2021-01-28 エディタス・メディシン,インコーポレイテッド 免疫療法のためのt細胞におけるcblbのcrispr−cas9編集のための方法、組成物および構成要素
US20210396739A1 (en) * 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20200063100A1 (en) * 2018-05-11 2020-02-27 Crispr Therapeutics Ag Methods and compositions for treating cancer
KR20220100913A (ko) * 2019-11-13 2022-07-18 크리스퍼 테라퓨틱스 아게 Cd70을 표적화하는 유전자 조작된 t 세포를 사용하는 신세포 암종(rcc) 치료법
WO2021108455A1 (en) * 2019-11-25 2021-06-03 KSQ Therapeutics, Inc. Methods for activation and expansion of tumor infiltrating lymphocytes
CN115297890A (zh) * 2020-02-03 2022-11-04 国立大学法人东海国立大学机构 用于对患癌的对象处置癌的抗meflin抗体和含有该抗体的药物组合物
MX2022015586A (es) * 2020-06-12 2023-03-15 Nkarta Inc Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.
JP7862361B2 (ja) * 2020-07-29 2026-05-19 ヤンセン バイオテツク,インコーポレーテツド Hla-g抗原結合ドメインを含むタンパク質及びそれらの使用

Similar Documents

Publication Publication Date Title
KR102777002B1 (ko) 항글리피칸-3 항체 및 이의 응용
JP7595696B2 (ja) Cd3抗原結合性断片及びその使用
JP7041516B2 (ja) 共通軽鎖を有する二重特異性抗体又は抗体混合物
RU2748281C2 (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
RU2451689C2 (ru) Новые антипролиферативные антитела
AU2020202667A1 (en) Cd20 binding molecules and uses thereof
EP4039705A1 (en) Antibody targeting bcma, bispecific antibody, and use thereof
IL258491B2 (en) Preparations and methods for inhibiting antigens of a particular lineage
KR102086656B1 (ko) Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도
RU2007145419A (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
JP2010509931A5 (cg-RX-API-DMAC7.html)
JP2021511811A5 (cg-RX-API-DMAC7.html)
JP2020530306A (ja) 多重特異性抗体とその作製及び使用方法
WO2022222910A1 (zh) 靶向gprc5d的抗体及其用途
HRP20110187T1 (hr) Multispecifične deimunizirane tvari koje vežu cd3
JPWO2015146437A1 (ja) 高機能性IgG2型二重特異性抗体
CN112955472A (zh) 抗ptk7免疫细胞癌症疗法
CN117858906A (zh) 与cldn18.2和cd3结合的双特异性结合剂
CN111620951B (zh) EGFP-Wnt2融合蛋白抗原和Wnt2单克隆抗体以及Wnt2单克隆抗体的应用
US20220275081A1 (en) Binding molecule specific for lrig-1 protein and use thereof
KR20240046224A (ko) 이중특이성 항체 및 그 용도
JP2023508674A5 (cg-RX-API-DMAC7.html)
CN101831434B (zh) 抗人cd45ra鼠免疫球蛋白可变区基因及用途
US20060154334A1 (en) Method of producing an antibody to epidermal growth factor receptor
AU2369101A (en) Antibodies against plasma cells